International Journal of Medical and Pharmaceutical Sciences
Open access peer-reviewed Journal
Volume 2, Issue 11, Page 89-106.
https://doi.org/10.5281/zenodo.24414465

Review Article

CADD in Cardiovascular Drug Discovery

Sanika Sabale*, Prasad Yadav

Ashokrao Mane Institute of Pharmacy Ambap.

Cardiovascular diseases (CVDs) are among the major causes of morbidity and mortality worldwide, creating a continuous need for the development of safer, more effective, and targeted therapies. Computer-Aided Drug Design (CADD) has emerged as an important computational approach in cardiovascular drug discovery by reducing the time, cost, and experimental effort involved in conventional drug development. This report provides an overview of the application of CADD in cardiovascular drug discovery, including Structure-Based Drug Design (SBDD), Ligand-Based Drug Design (LBDD), molecular docking, molecular dynamics simulations, quantitative structure–activity relationship (QSAR) modelling, virtual screening, pharmacophore modelling, and ADMET prediction. CADD can be applied to important cardiovascular targets such as angiotensin-converting enzyme (ACE), HMG-CoA reductase, PCSK9, phosphodiesterase, β-adrenergic receptors, and ion channels. It also supports the development and optimization of cardiovascular drug delivery systems such as drug-eluting stents, drug-coated balloons, liposomes, and nanoparticles. The integration of artificial intelligence (AI) and machine learning (ML) with CADD further improves molecular screening, activity prediction, ADMET assessment, drug design, and personalized drug delivery. Despite its advantages, CADD has limitations including data quality, biological complexity, difficulties in modelling cardiovascular physiology, computational requirements, lack of standardization, and the need for experimental validation. Therefore, computational predictions must be supported by in-vitro, in-vivo, and clinical studies. Future developments involving AI/ML, multi-omics, digital twins, hybrid multiscale modelling, and patient-specific computational approaches may further improve cardiovascular drug discovery and delivery. Overall, CADD provides a valuable framework for developing safer, more efficient, and potentially personalized cardiovascular therapies.

Keywords: Computer-Aided Drug Design (CADD), Cardiovascular Diseases (CVDs), Drug Discovery, Molecular Docking, Structure-Based Drug Design (SBDD), Ligand-Based Drug Design (LBDD), Virtual Screening, Molecular Dynamics, QSAR, Pharmacophore Modelling, ADMET Prediction, Artificial Intelligence (AI), Machine Learning (ML), Drug Delivery Systems, Nanoparticles, Drug-Eluting Stents, Cardiovascular Targets

INTRODUCTION:

Cardiovascular disease (CVD) is the most common cause of death in any country, so the continuous development of interest towards new small molecule, biologic, and enhanced delivery platforms (liposomes, polymeric nanoparticles, viral/non-viral vectors, drug-eluting stents/balloons) is justified. CADD: structure-based design (SBDD), ligand-based design (LBDD), molecular dynamics (MD), quantitative structure-activity relationships (QSAR), and even AI/ML, assists with various steps of discovery and delivery-design. The computational modelling of transport and hemodynamics connects the molecular design and performance of in-vivo delivery.

CADD consists of a very wide collection of in silico strategies: structure based drug design (SBDD), ligand based drug design (LBDD), quantitative structure activity relationship (QSAR) modeling, and molecular dynamics (MD) simulations, allowing the rational design of bioactive molecules to cardiovascular targets including angiotensin converting enzyme (ACE), HMG coa reductase, phosphodiesterase, beta adrenergic receptors, and b-professional cleaning kinase. These software application tools streamline discovery of new ligands, computing binding affinities, optimizing pharmacokinetic (PK) and pharmacodynamic (PD) properties, and initial toxicity of target proteins, which have been found to reduce experimental costs and times. The massive issues in the world include

heart diseases (CVDs) such as atherosclerosis, heart attacks, and coronary artery disease .Although medicine is fine, many drugs get to the wrong sites, fail to reach the ill sites, are difficult to assimilate, eliminated quickly, etc.

Drug-eluting stents (DES), drug-coated balloons (DCB), small particle carriers, and inhalation drugs are among the new delivery gadgets (DDS) that are being manufactured to overcome those challenges. Simultaneously, CADD technologies (such as developing drugs using protein shapes, prediction using known drugs, virtual search, modeling of molecules, and investigation of PK/PD) are accelerating the drug discovery and improving it.

Combining CADD and heart DDS would perhaps allow us to program the drug and the delivery procedure in an accurate, effective, and safe manner.

CVDs include heart attack, hypertension, heart failure, irregular heart beating, and others. With all the modern medicine, new medications on these heart issues are even to this day, a long, costly, and frustrating task. The traditional drug discovery process requires a time of over ten years, costs in billions of dollars, and on average, the drugs fail to pass clinical trial due to poor efficacy or unpleasant side effects. The CADD is a massive game-changer since it introduces prediction and logic into the game. In simulations the researchers are able to design potential drugs using computer docking, virtual screening and QSAR, prior to them being created in the laboratory or their evaluation. Combining computers and experiments leads to a reduced number of years wastage and experiments towards the new heart drug.

Computer Assisted Drug Design CADD involves applying computers to find out what molecules can cure a disease. It examines protein targets, chemical structures and it also speculates with how they will interact with each other, bind with each other and how they will be handled by the body.

• Classification

1) Structure-based drug design (SBDD):

Involves using the shape of proteins of interest (such as enzymes or receptors) to design novel proteins with the help of a 3-D shape Molecular screening Library screening to identify specific cardiovascular targets (ion channels, GPCRs, enzymes such as ACE, PCSK9-binding interfaces) -molecular docking. Molecular dynamics (MD) use them to refine binding modes, make residence times estimates, identify induced-fit or allosteric effects. These save the cost of testing in the laboratory and aid in prioritizing applicants to targets in cardiovascular. Functions when you are aware of the 3-D shape of the desired protein (such as an enzyme or receptor). The most important tools are docking and molecular dynamics.

Example: Researchers docked potential inhibitors to ACE (Angiotensin- Converting Enzyme) so as to deal with hypertension.

2) Ligand based drug design (LBDD):

Applied when we are not known to the shape of the target; applies known ligands to make inferences about interesting features, QSAR, etc .QSAR, pharmacophore modelling and similarity searches are extensively utilized in situations where structural data are not readily available. Different scaffolds meeting cardiovascular target qualities can be proposed by generative models and de novo design (deep learning). This is used when one knows nothing about the shape of the target but has molecules that do the job. You can easily identify what is similar in active compounds by modeling the key features (pharmacophores) and applying 3-D QSAR.

- **The Tools and Methods of Computations.**

Virtual screening (both ligand and structure - based) to boil down huge chemical libraries.

Molecular docking to determine the way the molecules will fit and the strength they will bind.

Molecular dynamics (MD) simulations in order to regard whether the molecules are stable or altered in shape. ADME/Tox prediction models to check which is absorbed, distributed, metabolized, excreted and toxic at an early stage.

Machine learning / AI techniques are emerging to facilitate the identification of patterns, anticipation of interactions, grading molecules, ADMET properties, off-targets, and optimization Deep learning, which is used to optimize formulations, predict ADMET properties, aids de novo generation of molecules and properties. ML integration has increased rates of hit-to-lead and lead optimization in therapeutic indications, such as cardiovascular indications and others.

- **Cardiovascular Drug Discovery: CADD Use In Cardiovascular Research**.

Discovering novel heart disease pathway-targeting small molecules (such as combating inflammation, oxidative stress or lipid metabolism).

Borrowing natural and marine compounds with unknown targets and attempting to use them to treat heart and brain diseases. The marine products have in-silico screening as an example of candidates to be spotted against cardiovascular and neurodegenerative conditions.

Giving medicines to block the activity of enzymes which lead to heart-related conditions in chronic diseases (such as aldose reductase inhibitors on diabetic heart) by designing an ability in CADD to optimize potence, selectivity and PK/PD.

- **The importance of CADD in Cardiovascular Research**.

1)Cardiovascular diseases are associated with a lot of proteins, receptors, enzymes and signaling pathways. It is difficult to design drugs which can precisely strike these targets. CADD helps by:

- Making molecules that the predictor is certain to work even before you make it.
- Reducing the rate of failure in real clinical trials.
- Determining drug interaction with the CVD-causing proteins.
- No More Punching names Verifying thousands of molecules and not in the lab.

Since the drugs related to the heart must be extremely safe (at least not causing rhythm issues), CADD detects the toxicity at a very early stage, too.

2) Target Recognition and Target Analysis. Identifying the correct target is the initial phase in any drug discovery journey- it is typically some protein that promotes the illness. In the case of cardiovascular diseases, the target is normally:

ACE and renin (monitor blood pressure) PCSK9 & HMG Co enzyme A reductase (Regulation of Cholesterol) PDE mg 5 (controls smooth muscle decontraction in blood vessels) P2Y12 receptor (platelets activation and clotting) Ion channels (central to arrhythmia).

3) Such targets are studied with the help of genomic and proteomic databases such as UniProt, KEGG, and the Protein Data Bank. After being aware of their form and their action, the drugs can fit in better. Structure Based Drug Design: Seeing How Drugs Reef. Once the shape of the target is known, CADD can visualize the shape of a prospective drug as though it were a key in a lock.

(a)Molecular Docking-

Docking includes the most effective mode of a drug to embrace the active location of a

protein. In cardiovascular study, docking would be useful:

Enhance ACE blockers such as lisinopril.

Safe and more potent statins.

Find new PCSK9 drugs to reduce cholesterol

Develop selective PDE 5 inhibitors of pulmonary hypertension.

Get improved antithrombotic medications to prevent heart attack and stroke.

AutoDock, Glide and MOE provide tools with binding scores and graphics of hydrogen bonds, hydrophobic contacts etg.

(b) Molecular Dynamics Simulations (MD)-

Proteins do not remain in one place but they are constantly wiggling. The MD simulations demonstrate a time-based action of the drug-protein complex.

MD has explicated in cardiovascular studies:

The mechanism by which statins remain stable within HMG - CoA reductase.

Why selective attachment of beta-blockers.

The body stability of PCSK9 inhibitors.

The impact of ion -channel blockers on heart rhythm.

MD provides among other stats RMSD and Free energy allowing us to refine drug molecules.

(c) Free Energy Calculations-

Methods such as MM 2 PBSA or FEP are used to determine the affinity with which a drug binds to a target. These calculations are used in design of:

Inhibition of rennin is more selective. Next-gen stations

Blood-thinners Direct factor-Xa inhibitors.

4) Ligand Based Drug Design: Known Drug Learning. In cases where our target structure is not in

the 3D form, CADD looks at the data of the available drugs.

QSAR (Quantitative Structure-Activity Relationship)

(a) QSAR- QSAR is a relationship coordinator of the chemical attributes with biological activity using math. It helps researchers:

Modify antihypertensive molecules. Enhance the anti-arrhythmic pharmacology. Increase the anti-platelet drug levels.

Reduction in side effects of calcium-channel blockers.

QSAR now utilizes machine learning to be more precise in its predictions.

(b) Pharmacophore Modeling

The important characteristics required to be active such as hydrogen-bond acceptors, hydrogen-bond donors, aromatic rings, and hydrophobic hoods are found in the pharmacophore models.

Pharmacophores have aided us in the cardiovascular drug design in the following ways:

What makes ACE inhibitors work

Advanced effects of powerful statins

Formulation required in P2Y12 blockers.

The chemical characteristics mandated to inhibit PDE-5.

These models help us to search new molecules of similar characteristics.

5) Virtual Screening Searching Millions of Molecules in a Flash. Conventionally screening is expensive and time consuming. Virtual screening allows us to screen millions of compounds in a matter of hours.

Screening of molecules through virtual screening is done in cardiovascular research to identify molecules: Inhibit PCSK9 and reduce the LDL cholesterol.

Demonstrate antithrombotic effect, no bleeding.

Have tight bonds with ACE and rennin Act as new beta-blockers Prevent platelet clumping

Millions of virtual compounds are stored in libraries such as ZINC, PubChem and Enamine, and filtered using docking, pharmacophore or machine-learned models.

6) The ADMET and Cardiotoxicity predicted.

The heart drugs enter the heart directly and therefore, safety is paramount. CADD predicts:

Absorption and solubility Oral bioavailability and lipophilicity.

Liver metabolism Toxicity and cancer risk And dangerous arrhythmias may be caused by especially hERG channel blockage.

Such tools as SwissADME, pkCSM, QikProp and Derek Nexus evaluate these risks prior to laboratory work.

7) Cardiovascular Drug discovery through AI and Machine learning.

AI is used in creating models to identify patterns, predict activity and scale up to novel molecules used in modern cardiovascular research.

AI apps include:

Ironic location of antihypertensive peptides in food proteins.

Developing new PCSK9 inhibitors

Forecasting QT -prolongation and toxicity of antiarrhythmics.

Creating new buildings using deep learning.

Determining dynamics in complicated networks such as the RAAS system.

Deep Chem, ChemProp and Alpha fold are the tools supporting such tasks.

8) Systems Biology and Network Pharmacology.

Cardiovascular diseases tend to have a plethora of directions. CADD has ties into systems biology tools to see whole-body effects.

Network pharmacology maps interactions of:

- Drugs
- Genes
- Proteins
- Pathways

This aids in identifying multi-target drugs or drug combinations in such disease conditions as high blood pressure or atherosclerosis.

• Cardiovascular drug Dilivery computer modelling Multiscale transport models

1) BPK models are able to determine the systemic kinetics and organ distributions that are significant

with cardio-active drugs (e.g., predicting heart tissue exposure and systemic side effects). Models used to simulate blood flow, shear stress, and particle/drug molecule transport include CFD and fluid-structure interaction (FSI) models - are important to intravascular delivery strategies (stents, balloons, catheter infusions). These models are capable of forecasting the location of nanoparticles and device geometry influences the dispersion of the drugs.

2) Device-oriented modelling

Drug-eluting stents/balloons: optimization of the coating thickness, polymer erosion rate and diffusion-convection rate are done by the use of diffusion-convection models, finite element analysis and coupled drug-tissue interaction simulations to produce therapeutic tissue concentrations without toxicity. The latest reviews elaborate computational optimization procedures applied to drug-eluting devices.

3) Nanocarrier design and predictive modelling.

Designing nanoparticles in silico Prediction of protein corona formation, particle margination in flow, and organ targeting based on physics-based or ML simulations can serve to design carriers (liposomes, polymeric NPs, exosomes) to target the myocardium or a vascular wall. Ligand-receptor pair screening, which is computed, directs the targeting of oxidative myocardium or endothelium with the use of targeting moieties.

- **CVD clinical uses and applicability.**

1) Discovery of small molecules discoveries in cardiovascular targets.

CADD has aided in identifying/optimizing inhibitors/modulators to include PDEs, ion channels, and also enzymes (ACE, PCSK9). The reviews list the recent achievements and how in silico activities expedited such projects.

2) Biologic and nucleic-acid therapeutics.

Epitpeptide mapping in vitro, computational structure prediction and optimization, and computational evaluation of delivery vectors (viral capsid design parameters or lipid nanoparticle formulation parameters) have diminished experimental cycles in nucleic-acid therapeutics to cardiovascular disease (e.g., gene therapy to heart failure, RNAi to cardiovascular disease pathological mediators).

3) Nanoparticle mediated targeted delivery (case studies)

Surveys of the ML/CFD of the nanoparticle parallel transport in arterial flow and experimental studies of the magnetic targeting or ligand density to meet the requirements of vascular wall deposition indicate the ability of computational design to provide better targeting effectiveness in preclinical systems. A study published in 2024 used ML to optimize the delivery of nanoparticles under the flow condition of the cardiovascular system.

4) Drug delivery that is incorporated in a device.

Computational: The modelling of drug-eluting balloons and stents is used in choices of polymer, drug load, and release kinetics. Clinical outcomes have been interpreted through modeling and the next-generation devices have been designed which enhances tissue retention and lowers restenosis.

- **Combination of formulation/engineering and CADD.**

In closed-loop design strategies, the active molecules are selected/modifications are done by CADD, the behaviour of the nanoparticles and their release rate are determined by formulation modelling and system-based PK/PD models, and the process is in turn refined to optimal therapy.

Example pipeline: (1) SBDD/ML to propose the cardioprotection small molecule - (2) in silico ADMET/solubility optimization - (3) Select the nanoparticles platform using the predictive models of encapsulation & release - (4) use of CFD/PBPK to simulate the delivery to blood vessels and exposure to tissues - (5) focused in vitro/in vivo validation. These integrative strategies have become a significant trend in reviews.

- **Advantages: expediency, price and mechan ready sense.**

The key benefits are less screening expenses, quicker hypothesis-testing, mechanistic understanding of binding and transport and (finally) the chance to examine parameter spaces (ex: particle size, ligand density, flow conditions) otherwise prohibitive experimentally. These advantages have been reported in the literature of reviews multiple times during 2021-2024. Limitations and challenges Data quality: The

quality of the data also relates to the complexity of the entire field of biology.

1) Data quality & biological complexity : Structural/biological data is only as good as CADD can make it. For many cardiovascular targets, incomplete knowledge of the structure, complex allostery and disease-specific microenvironments (ischemic tissue vs. healthy myocardium) limit the predictive accuracy.
2) Translational gaps : Variations between simulated and in vivo physiology e.g., immune opsonization, interstitial transport in fibrotic myocardium and variation in patients pose translational challenges of delivery systems. PBPK and PBPD models are being advanced but they need solid validation.
3) Regulatory/ reproducibility problems : There is a change in regulatory acceptance of models to be used in decision-making (e.g. to select first-in-human dose or to design a device). The priorities of the community are model transparency, validation datasets and standardization.

Consideration of regulation and ethics Model-informed drug development (MIDD) contributions are becoming more widely tolerated by the authorities however cardiovascular delivery systems (combination product: device + drug) require coordinated assessment. Regulatory trust will predominantly be the key to model standardization and comprehensive external validation. New guidance promotes early relationships with regulators whereby models are used to inform clinical decision points.

- **Directions and opportunities in the future.**

1) Multi-omics, digital twins and customized delivery. Integration of patient specific imaging, genomic/omics data and digital twin frameworks could enable individualised approaches to delivery (e.g. stent coating choices or nanoparticle dosing tailored to patient hemodynamics). There are emergent studies in early computational clinical-translation.
2) Improved physics + data fusion Hybrid physics/ data-driven models using first-principles (CFD, MD) and data-driven ML/AI probably would perform the best in predicting tasks such as intravascular nanoparticle targeting.
3) High concepts in silico screening of formulations Automated in silico formulation screening (polymer selection, ligand density, release profile) coupled with optimization will save time to an optimal delivery system and allow an exploration of formulation space to be more systematic.

Practical suggestions to the researchers.

Obey to Structure-based CADD (docking + MD) where high quality structures are available, to complement with ligand-based and ML otherwise as well.

Molecular design Early ADMET and formulation $-compatibility screens will prevent late failures. Use multi scale models (MD -mesoscale - CFD/PBPK) in the transition of molecule -carrier-organ delivery.

Confine computational predictions through hierarchical experiments (in vitro - ex vivo flow models - small -animal, followed by large -animal models). Document, version, and regardless of possible, share models and data for a better ability to reproduce and instill trust in regulators.

• Workflow of CADD

Section	Details
Workflow of CADD	- Pick and check a target - Discover hits using virtual screening. - Maximization of hits into leads. - Predict ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) - Test in cells and animals
Programs / Software Used in CADD	Predicts drug binding and complacency: AutoDock, Glide, GOLD, Predicts drug binding and strength of binding -Schrodinger, Open3DQSAR Measures the relevance of the structure to activity
Simulation Tools	GROMACS, AMBER Simulation of protein-drug combo stability
ADMET Prediction Tools	pkCSM, SwissADME Canopy Science Looking at drug - likeness and possible toxicities

- Cardiovascular Drug Discovery Application CADD.

CADD aids in the identification and optimization of drugs to enzymes, receptors and ion channels associated with heart diseases.

1) The identification of targets in CVD

Sr. No	Target	Role / Function	CAAD-Related Insight
1	HMG-coA Reductase	Control cholesterol levels	Statins development was computer-enhanced
2	Angiotensin-Converting Enzyme (ACE)	Control antihypertensive target	Docking helped in Creating better captopril cousins
3	B-Adrenergic Receptor	GPCRs acting against arrhythmias and heart failure	
4	Cyclooxygenase-2 (COX-2)	Manages inflammations-induced heart complications	

2) Case Studies

Sr. No	Drug/Compound	Target	CADD Technique	Result
1)	HMG-CoA reductase	HMG-coA reductase	Docking, QSAR	Better cholesterol control
2)	Losatan Angiotensin	Angiotensin2 receptor	Pharmacophore modelling	Powerful antihypertensive action
3)	Ivabradine	HCN channel	Virtual screening	Lowered heart rate, no contractility dip

3) Natural Product-Based CADD

The good blend of flavonoids, alkaloids, terpenes in nature has heart benefits. In vitro natural library scans assist in the identification of lead molecules which are less toxic and bioavailable.

- Advantages of CADD

Fast – gets hits quicker.

Cheap– cuts down on lab work.

Accurate - predicts of binding and body handling.

Twice less animals used - There are fewer live tests done through toxicity examinations that are carried out in the first phases.

Drug-recycling - reinvents old drugs.

- Limitations of CADD

- Skilled to the accuracy of protein /ligand pictures.

- Models may miss some biology.

- It can't replace the lab.

- When we are not well aware of the heart target, the predictions can fail to reach the target.

- **New Trends in CADD in the Cardiovascular System.**

Artificial Intelligence and Machine Learning is an educational content-area focused on stakeholders and vendors with the aim of operating more intelligent systems and machines.

1)Artificial Intelligence and Machine Learning Workload is an educational content area centered on stakeholders and vendors that work to operate more intelligent systems and machines.

2)AI/ML slants room binding strengths, ADMETs and some others. Deep-learning has the potential to even generate brand-new molecules to targeted molecules in the heart.

3)Drug Repurposing The applications of already used drugs are detected with the aid CADD. As an example, sildenafil (initially developed to treat high BP) was repurposed on pulmonary hypertension using virtual screens.

4)Multi-Target Drug Design The heart disorders confound numerous pathways, oxidative stress, inflammation, lipid play. CADD allows investigators to design drugs that target multiple locations simultaneously.

5)Omics and Systems Biology Investigation. The inclusion of genomics, proteomics, and metabolomics as an addition to CADD brings new biomarkers and individualized drug regimes.

- Future Perspectives

- AI-driven predictions.
- Cloud-based virtual screens.
- Structural biology, e.g. CryoEM and AlphaFold2.
- Customized CADD to target patient-exclusive medicine.
- Open data enables individuals to innovate at an accelerated rate

CADD will become the heart of the future drug design, binding computer conjectures with clinical actuality.

- **Use of CADD in Designing Cardiovascular DDS.**

This is the place CADD and drug delivery collaborate and complement one another.

In this way, drug release kinetics can be modeled (as shown below).

Predicting the coming out of stent coating, nanoparticles, etc.: computational models (deterministic and stochastic) can be used. These assist in fine-tuning such aspects as diffusion, thickness of materials and binding.

The best prediction of the objective is called Targeting and Specificity.

The identification of markers that are abundant in sick heart tissue compared to normal tissue enables designers to develop molecules (antibodies, peptides) through CADD to target nanoparticles or coating.

1) Safety / Toxicity Profiling

Early (in-silico) prediction of off-target interactions, cardiotoxicity and immunotoxicity.

2) Pharmacodynamics and Pharmacokinetics Optimization.

CADD selects drugs with the appropriate half-life, solubility and stability, which is important in delivery systems such as coated stents, which has a low drug capacity.

• Existing Problems and shortcomings:

Most computer models are unable to fully represent the disordered reality of blood flow, wall shear stress and tissue differences in the cardiovascular system. It is not easy to translate computer predictions into actual lab or clinical outcomes: most engineered molecules or delivery devices do not do as well in living organisms or patients.

There are issues of expanding production, expenditure and obtaining sanctions by the regulators.

The design of DDS requires computer scientists to cooperate with materials experts, biologists, and doctors to incorporate CADD into the design.

Future Directions: Better multiScale models associating molecular design to device level (like stent form, fluids)

Prediction of the functioning of delivery devices in varying conditions of the body (release, targeting) using AI/ML.

Computer-assisted design (CADD) Smart, responsive systems (triggered by pH, shear, enzymes). Better vehicles (more biological therapies) of heart disease, using gene therapy and RNA drugs, enhanced through computer design.

Personalized medicine: using patient-specifc anatomy and molecular markers in personalized drug resonance: modelling tweak data.

• Role of CADD in Advancing Cardiovascular Drug Delivery System

Besides molecular discovery, CADD currently is playing an important role in the optimization of drug delivery in cardiovascular therapy. Computational models at the multiscale, including physiologically different models, such as pharmacokinetic (PBPK) simulations, and computational fluid dynamics (CFD) permit accurate prediction of the drug distribution, vascular transport, and retention in tissues. These simulations hold great importance in the development and optimization of drug-eluting stents, drug-coated balloons, and nanoparticle-based delivery systems to guarantee that the drug is released under controlled and specific site-targeted conditions in the cardiovascular systems. As an example, the CFD and finite element modeling are used to understand the diffusion of drugs across the stent coatings to the arterial walls whereas the machine learning algorithms are used in predicting the behavior and the efficiency of nanoparticles in targeting under the condition of dynamic blood flow.

CADD combined with the application of nanotechnology has continued to develop cardiovascular therapy. In silico modeling can be useful in the rational design of liposomes, polymeric nanoparticles as well as lipid-based carrier, and it can target ischemic myocardium or inflamed endothelium. Predictive computational methods model parameters including particle size, surface charge, ligand density and systemic toxicity biodistribution can be improved by reducing systemic toxicity. These inventions have led to the development of personalized drug delivery mechanisms, where the computational models are used to customize the therapy to the patient-specific physiological and disease characteristics.

Nevertheless, despite this possibility, there are still a number of challenges. Concomitant limitations between inadequate biological data quality, structural uncertainty on the structures of complex cardiovascular proteins, and the dynamic nature of the blood flow states pose a challenge before accurate in silico predictions can be achieved. In addition, the mathematical computation of the derived results into clinical outcomes would need strong validation by experimental and clinical studies. The use of model-inspired drug development (MIDD) in the cardiovascular products is in a developing area that requires standardized procedures, transparency of models, and reproducibility. Finally, CADD will provide a cardiovascular drug discovery and delivery paradigm shift as a synthesis of molecular design, formulation engineering, and system-level modeling into a single working process. It has the potential, due to its capacity to model the interactions of atoms all the way to physiological scale, to provide a novel avenue of making safer, more efficient and patient-specific therapies. With the emerging developments in computational power, AI-driven prediction and digital twin, CADD will have an opportunity to fill the gap between theoretical design and clinical translation and open a new era of precision cardiovascular medicine.

• Implications of Machine Learning in Computer-Aided Drug Design (CADD)

I believe that the drug design is being transformed by ML completely. Researchers have developed pattern-recognition tools that combine these faster guesses as to which drugs to work based on gut feeling however, unlike today when they rely on intuition and the tools that are available, researchers can quickly search through vast quantities of data, such as molecular structures, bioactivity logs, and chemical properties, to make intelligent guesses about which drugs to explore. This implies that the initial phases, the identification of good starting compounds, optimization of leads, and also anticipating the behavior of a drug in the body can be done much faster and at a low cost.

In the event of structure-based design, ML can be used to make the scoring scores more precise, the hits of the virtual screen are ranked higher and even how a drug will change shape to suit a target can even be predicted. The models outcompete outdated scoring systems since they are capable of identifying non-linear patterns that are complicated and which simpler mathematics are unable to detect. The same is true in the case of ligand based design: ML is better than QSAR models because they provide more accurate predictions even in the cases with mixed or high-dimensional data available.

Deep learning is taking it one step further. It becomes possible to create entirely novel molecules that are druglike, readily synthesizable, and targeting the correct target (with such tools as variational auto-encoders, recurrent neural networks, GANs, and more recent diffusion models). It feels like a creative robot

capable of presenting to you worlds of chemistry that you never thought you would see ever.

ML is also a big deal later in the development of drugs. Early prediction of ADMET (absorption, distribution, metabolism, excretion, toxicity) enables scientists to identify the issues early on in their product instead of turning them into costly failures. ML is useful in streamlining items such as nanocarriers, polymer messages, lipid formulations and even heart related delivery devices as used in drug delivery. It calculates optimal material characteristics, launch date, tricks aiming, and distribution of the drug within the body providing us with a smarter method of providing treatment. But it's not all sunshine. A good model requires feeding it with high quality data with diversity and hence standardizing data is a big task. Models may be untrustworthy because they overfit, are not easily interpretable or absorb bias due to limited data, and should not be applied in new situations. This is the reason why the real experiments and a good theoretical background is still required to support what the AI is saying.

Overall, ML is transforming CADD as a mostly trial-and-error discipline into a science driven by data that is capable of making predictions. I believe, with computer power, improved data, and algorithms the same part will continue to increase with ML in designing smarter drugs and smarter ways of delivery.

• Integration of machine learning and AI in CADD

The next to Computer-Aided Drug Design (CADD) in collaborating with machine learning (ML) and artificial intelligence (AI) are now the final two best friends as the latter duo starting to take part in heart-based medications. Scientists no longer need to conduct countless lab experiments, or to guess and hope and hope, but rather to utilize ingenious software programs with a capability to learn when a vast amount of data is employed those concerned with how a drug will act inside our cardiovascular system. It implies that they would be able to develop safer, more effective and individually desired treatments, based on the unique body of the person.

Rational Design Drugs Smart Tools.

AI and ML make drug development calculations and experiments faster and more precise at the preliminary stages. The instruments can sift through wall-to-wall amounts of biological data, such as genes, proteins, markers of diseases and disease and narrow down which aspect of the heart or blood vessel is to be targeted. When the target is known, AI algorithms may offer drug molecules that may bind optimally, and can even predict the safety and toxicity level of the drug, as well as its absorption. This reduces the amount of experiments that are a waste of time and allows researchers to concentrate on the most promising ones at a faster time.

Adequacy of Knowledge of How the Drugs move in the body better.

Among the most difficult riddles of cardiovascular therapy is how a drug can get the damaged area when traveling through the blood vessels. ML and AI collaborate with flashy CADD programs such as PBPK model (to map the distribution of drugs to various organs) and CFD (to investigate blood circulation). AI enhances these models by finding the patterns that humans can miss, for example:

- the duration taken by a drug in the blood,
- its penetration into the heart tissue, and
- the possible different responses of people with heart failure or kidney disease.

These lessons assist physicians in adjusting doses and avoiding drug side effects.

Big Data Techniques in Biotechnology, Moving toward Better Nanoparticles and Drug Carriers.

Nanotechnology becomes cooler to introduce medications directly to the ailing heart tissue or the swollen arteries. However, creating the ideal nanoparticle is difficult since thousands of details count in: size, surface coating, charge, drug release rate, etc. ML intercedes by screening thousands of designs and informing researchers which designs will:

- strike the heart better still with more force,
- avoid the undesirable immune responses, and
- dispense the drug with the appropriate rate.

In so doing scientists will be able to select the most appropriate design without having to create hundreds of prototypes in the lab.

Improvement of Drug-eluting Stents and Balloons.

A popular method to maintain the openness of the arteries and to deliver medication directly to the walls of the vessels is in the form of drug-eluting stent

(DES) and drug-coated balloons (DCB). The key role that AIs play in this is by predicting:

- the rate of movement of the drug through the stent coating,
- and how far into the bottom of the vessel,
- what areas of the artery could receive reduced drug concentrations, and
- how to customize the type of stents to fit various patients.

The result- The drugs released are distributed evenly and more effectively.

Towards Personalized Therapy of the Cardiovascular System-

Personalized treatment is one of the most amazing facts about AI-based CADD. Each person has a different cardiovascular system - blood pressure, cholesterol, the functioning of the heart, the shape of the vessels, their genes are all different. AI has the potential to sew together data of:

- medical scans (CT, MRI),
- clinical records,
- blood tests, and
- genetic markers

to develop a data replica of a patient. That computer model will be able to determine how that drug will react in that particular individual and will assist the physicians in selecting the appropriate drug, dosage, and even the correct stent or nanoparticle to that particular individual.

Challenges that are yet to be solved.

Though AI and ML bring huge perks, but there are still bumps in the road:

- We still do not have sufficient good cardiovascular statistics.
- There are AI models that are black box in nature and thus it is difficult to know how they make their predictions.
- Predictions thus must be tested against the actual results of lab and clinical tests.
- There must be clear guidelines and standards to ensure that the outcomes are correct and reproducible.

Despite these problems, the discipline is a rapidly evolving one.

• Future Outlook

AI + ML + CADD has the potential of revolutionizing completely how we develop and deliver heart drugs. Computers are getting intelligent:

- smarter nanoparticles capable of hitting diseased tissue down to the point,- stents which vary their drug delivery with real-time determination of the blood flow, and- customized delivery mechanisms that were fitting the bodies of respective patients like gloves.

Altogether, this combination is moving cardiovascular medicine to a new stage of accuracy, safety, and effectiveness.

- **CADD Experimental Validation: In-Silico to Laboratory**.

The interface that links the guesses made by the computer and the real world is experimental validation. Although computer-aided drug design (CADD) can fast scan libraries of chemicals, suggest the way they will bind themselves to targets, and how they will act in a body, we must still do the actual lab work to find out whether these predictions are working. Combining in-silico with in-vitro/in-vivo approaches keeps the mathematics within a biological context and results of CADD are more useful and credible.

Relevance of Experimental Confirmation: Computer models often take shortcuts - using, for example, rough scoring formulas, simplified force fields or big data guesses - that can overlook messy reality of proteins moving, cells interacting or whole organisms reacting. Experimental validation identifies and eliminates the fake hits, refines the actual hits, and reveals the breaches of the computer assumptions. Even the finest virtual hits may end up in failure without the lab tests since they do not dissolve, are not stable or they are poisonous.

In-Vitro Tests: Preliminary Test.

In-Laboratory tests test whether the computer predictions are valid or not. These tests examine or test direct molecular interactions such as whether an enzyme is inhibited, how a receptor interacts with a drug, or whether a pathway is altered: Biochemical tests are positive in docking and scoring by measuring a binding affinity (e.g. IC50, K).- Cell based tests are directly used in living cells, in which signal translocation, cell growth, or cell death are tested.

Biophysical gimmicks such as surface plasmon resonance (SPR), isothermal titration calorimetry (ITC), and thermal shift assays provide values on the actual clingage of the drug and target with each other and the impact of heat on the same.

Such experiments decouple real actives and computer fluff and are refinanced by models or QSAR predictions.

Structural Verification-

To check the position of a drug in its binding position we invoke structural techniques such as X-ray crystallography, NMR and cryo-EM. Using the lab-resolved structures versus predicted poses by computers it is possible to:

- Test the docketing, whether correct,
- Positioned concealed reactions eluded by the computer,
- Make improvements on scoring methods and force fields.

These structural feedback loops are essential towards the following design round.

In-Vivo Assessment

Animal experiments take the next step ahead, examining the pharmacokinetics (movement of the drug), its localization (biodistribution), deposition (metabolism), and efficacy of this particular drug in a living structure. This makes it clear whether the predictions of ADMET and safety vibes are valid in the messy body. In-vivo can also exhibit cell test characteristics (immune response or tissue penetration), which have been lost.

Information Straddling In-Vitro and In-Silico Result.

The second best part of the modern CADD is the back-and-forth between computer-modelled and lab results. When predictions fail to conform to reality we:

-re-train machine-learning models,

- Tweak QSAR equations,
- Recalibilate docking and scoring, and
- Beef up pharmacokinetic instruments.

The cycle improves the computer predictions as well as makes the subsequent experiments more targeted.

Participation in Drug Delivery and Formulation studies.

In drug delivery systems, such as nanoparticle, polymer carrier, implants or heart-delivery systems, experimental tests confirm the computer guesses on:

- The conversation between the carrier and the drug,
- How fast the drug releases,
- How perfectly it strikes the proper place,
- Its stability and safety in actual tissue.

Body conditions (shear stress on arteries, pH changes, enzymes eating things up) as lab simulations do ensure that our design of delivery is behaving in the way we expect.

Problems and Future Projections.

The central obstacles are due to the fact that computers work based on simplified world, whereas, biology is sloppy. Mistakes may be caused by prejudiced information, scientific shortcomings, or press-of-nerves constraints. The following developments are likely to take place in the future:

- Intense blend of machine learning with quality laboratory information,
- Automated closed loop (AI experiments on-the-fly) systems,
- Improved hybrid computer-laboratory operation, and
- Larger faster screening clouds of high-throughput experiments.

• Challenges and Limitations in CADD

Although Computer-Aided Drug Design (CADD) has transformed to become a potent instrument in the production of cardiovascular therapies, it continues to experience a number of challenges in the real world. The given limitations complicate the process of relying solely on computer models and ensure that laboratory studies and clinical research are not less crucial.

A dearth of Adequate Biological information.

CADD models are as good as the data that had been used to construct them.

We often do not have in cardiovascular diseases: full knowledge of the noteworthy proteins,

sufficient patient specific data, or pictorial descriptions of diseased arteries.

In case the data is weak, models are unable to make predictions.

The Heart and Blood Vessels are very complicated.

The heart does not just have it easy. Blood does not flow evenly, but vibrates, quickens, and rubs against the walls of vessels.

Because of this: Blood flow can hardly be modeled.

The arteries may also become rigid, bulky or become obstructed in unforeseen patterns.

The hearts of each patient act in various ways.

The aim of CADD models is to simplify these factors and with simplicity the outcomes might not necessarily reflect the reality.

Challenges Between Small-Scale and Large-Scale Models.

Cardiovascular drug delivery does not only happen on a single level:

proteins that interact with the molecules, drugs entering cells, chemicals diffused in tissues, and lastly by passing through the whole heart and blood massages.

It is difficult to find a single correct model where all these scales are connected. One error in any of the elements of the model can influence the whole prediction.

The Mathematic Models are not a Perfect Replica of the Diseased Arteries.

The behaviour of diseased arteries is very different as compared to healthy arteries.

Plaques, clots, inflammation as well as calcification all alter the movement of drugs and the response of tissues.

The majority of CADD models have been constructed on ideal or simplified arteries.

Because of this:

prognoses of diseased arteries are likely to be false, The performance of stent or nanoparticle can be overclaimed.

Difficulties in the Nanoparticle and Stent-based Systems Design.

Complex systems to work with are nanoparticles and drug-eluting stents. The success of them is also determined by numerous factors such as size, shape, coating level and the rate of drug release.

Recent CADD models have difficulties in anticipating completely:

interaction of nanoparticles and blood cells, the impact of blood flow on stent drug coating,and the diffusion of the drug within the vessel wall.

Such uncertainties may create discrepancies between the computer forecasts and the reality.Challenges Soft Landing Computer Simulations into Clinical Practice.

A model might be able to predict something, but it is not easy to implement the prediction into a clinical decision.

Doctors would like a simple rule, including:

how much drug to give, which stent to choose, or the duration of response of a drug.

However, a lot of them provide complicated outcomes, which cannot be easily interpreted by specialists and thus cannot be applied to a common clinical practice.

Great Processing speed and skills.

More sophisticated models such of CFD, PBPK, or AI based models need: powerful computers,

special software, and talented computer scientists.

Their availability is restricted to big hospitals and smaller research labs, which do not have access to them.

Absence of General Principles and reproducibility.

Various researchers apply varied assumptions and approaches in their models.

It results in inconsistent research and it becomes hard to:

compare findings repeat experiments or conform to regulatory provisions.

In the absence of standard guidelines, it takes a long time to be accepted by regulatory agencies.

AI Models Can Be a "Black Box"

AI and machine learning are prone to giving predictions without giving explanations on how they got those.

This is not transparent and this is a problem of lack of trust, particularly sensitive issues such as treatment of heart diseases.

Regulators and doctors are reluctant to trust a system which they do not comprehend fully.

Moral and confidentiality issues. Some data of a patient, including scans, genetic data, and medical history, is often used in the development of a personalized model of drug delivery.

This raises questions about:

data privacy, security, and personal medical information ethical use.

There should be appropriate guidelines, which would guarantee patient safety and confidences.

In Simple Words CADD is highly prospective although it is not flawless.

Poor availability of data, the intricacy of the heart, constraints of computer modeling, and real-life clinical problems are all obstacles to complete reliance on computer-aided drug design.

With more accurate data, more sophisticated AI models, and increased cooperation between engineers and biologists with doctors, most of these issues can easily be addressed in the future.

CONCLUSION:

Computer-Aided Drug Design (CADD) has been discovered as a revolutionary process of drug delivery to the heart, occupying the gap between molecular design, device-engineering and system-level modeling. CADD will allow more rational and targeted and patient-specific design of therapies, including drug-eluting stents and coated balloons as well as nanoparticles-based carriers, integrating tools such as PBPK simulations, CFD, finite-element modeling, and AI/ML. These in silico assists in the prediction of how drugs are spread, maintained, and functioning in the complicated hemodynamic milieu of the blood vessels and alleviates the experimental load, conserves time, and may enhance the safety and effectiveness.

Nevertheless, there are still a number of challenges. CADD has not yet reached its full potential due to the accessibility and quality of biological data, particularly of diseased cardiovascular tissues. Cardiovascular drug delivery is multiscale due to the ability of interactions between molecules and entire body organs to influence blood circulation, hard to model with precision. There are also barriers such as computational requirements, model transparency and non-standardization which are barriers to clinical translation. In addition, it is necessary to validate in silico predictions in real life scenarios by conducting rigorous in vitro, animal and humanized studies.

In the future, AI combined with CADD and creation of so-called digital twins, application of hybrid multiscale modeling promise to introduce a new era of precision cardiovascular therapy. With the ever-increasing computational power and data resource, it is probable that CADD based strategies will be at the center of designing a safer, more effective and personalized cardiovascular therapy.

REFERENCES

1. Morris P.D., Narracott A., von Tengg-Kobligk H., et al. Computational fluid dynamics modelling in cardiovascular medicine. Heart. 2016;102 (1):18–28.
2. Morlacchi S, Migliavacca F. Modeling stented coronary arteries: where we are, where to go. Annals of bio. medical engineering. 2013 Jul;41 (7):1428-44.
3. Bozsak F, Gonzalez-Rodriguez D, Sternberger Z, Belitz P, Bewley T, Chomaz JM, Barakat AI. Optimization of drug delivery by drug-eluting stents. PloS one. 2015 Jun 17;10 (6):e0130182
4. Migliavacca F., Gervaso F., Prosi M., Zunino P., atherosclerotic Minisini S., Formaggia L., Dubini G. Modelling drug-eluting stents. Comput Methods Biomech Biomed Engin. 2007;10 (1):63-73.
5. Calo VM, Brasher NF, Bazilevs Y, Hughes TJ. Multiphysics model for blood flow and drug transport with application to patient-specific coronary artery flow. Computational Mechanics. 2008 Dec;43 (1):161-77.
6. Sarker S, Chatzizisis YS, Terry BS. Computational optimization of a novel atraumatic catheter for local drug delivery in coronary plaques. Medical engineering & physics. 2020 May 1;79:26-32.
7. Alzhrani RM, Aldawsari MF, Alamoudi JA. Theoretical investigations on modeling blood flow through vessel for understanding effectiveness of magnetic nanocarrier drug delivery systems. Frontiers in Medicine. 2024 May 22;11:1397648.
8. Sliwoski G, Kothiwale S, Meiler J, Lowe Jr EW. Computational methods in drug discovery.

Pharmacological reviews. 2014 Jan 1;66 (1):334-95.

9. Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des. 2011;7 (2):146–157.
10. Sarma H, Upadhyaya M, Gogoi B, Phukan M, Kashyap P, Das B, Devi R, Sharma HK. Cardiovascular drugs: an insight of in silico drug design tools. Journal of Pharmaceutical Innovation. 2022 Dec;17 (4):1484-509.
11. Llorach-Pares L, Nonell-Canals A, Avila C, Sanchez-Martinez M. Computer-aided drug design (cadd) to de-orphanize marine molecules: finding potential therapeutic agents for neurodegenerative and cardiovascular diseases. Marine Drugs. 2022 Jan 5;20 (1):53.
12. Askr H, Elgeldawi E, Aboul Ella H, Elshaier YA, Gomaa MM, Hassanien AE. Deep learning in drug discovery: an integrative review and future challenges. Artificial Intelligence Review. 2023 Jul;56 (7):5975-6037.
13. Martinelli DD. Generative machine learning for de novo drug discovery: A systematic review. Computers in Biology and Medicine. 2022 Jun 1;145:105403.
14. Gao K, Nguyen DD, Chen J, et al. Generative deep learning for drug design. Front Pharmacol. 2023;14:112233.
15. Sícho, M., Stork, C., Svozil, D., & Karelson, M. (2021). Advances in structure-based drug design for cardiovascular targets. Drug Discovery Today, 26 (5), 1185–1197.
16. E, Spyrou G, K Vassilatis D, Cournia Z. Structure-based virtual screening for drug discovery. Curr Top Med Chem. 2014;14 (16):1923–19316. Gurung AB et al., An Updated Review of Computer-Aided Drug Design and … (2021). PMC review on CADD fundamentals and applications.
17. Niazi SK, Mariam Z. Computer-aided drug design and drug discovery: a prospective analysis. Pharmaceuticals. 2023 Dec 22;17 (1):22.
18. Wang K, Huang Y, Wang Y, You Q, Wang L. Recent advances from computer-aided drug design to artificial intelligence drug design. RSC Medicinal Chemistry. 2024;15 (12):3978-4000.
19. Omidian H, Babanejad N, Cubeddu LX. Nanosystems in cardiovascular medicine: advancements, AboArab MA, Potsika VT, Pleouras DS, Fotiadis DI. Computational modeling of drug-eluting balloons in peripheral artery disease: Mechanisms, optimization, and translational insights. Computational and Structural Biotechnology Journal. 2025 Aug 7.applications, and future perspectives. Pharmaceutics. 2023 Jul 12;15 (7):1935.
20. Akhtar Y, Ahmad S, Khalid F, Junjua MU, Aryanfar Y, Hendy AS, Tlija M, Soliman AT. Machine learning-a new paradigm in nanoparticle-mediated drug delivery to cancerous tissues through the human cardiovascular system enhanced by magnetic field. Scientific Reports. 2024 Sep 27;14 (1):22048.
21. Fumagalli I, Pagani S, Vergara C, Adebo DA, Del Greco M, Frontera A, Luciani GB, Pontone G, Scrofani R, Quarteroni A. The role of computational methods in cardiovascular medicine: a narrative review. Translational Pediatrics. 2024 Jan 24;13 (1):146.
22. Abughalia A, Flynn M, Clarke PF, Fayne D, Gobbo OL. The Use of Computational Approaches to Design Nanodelivery Systems. Nanomaterials. 2025 Sep 3;15 (17):1354.
23. .Yang F, Xue J, Wang G, Diao Q. Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases. Frontiers in pharmacology. 2022 Sep 12;13:999404.
24. Ng JC, Toong DW, Ow V, Chaw SY, Toh H, Wong PE, Venkatraman S, Chong TT, Tan LP, Huang YY, Ang HY. Progress in drug-delivery systems in cardiovascular applications: stents, balloons and nanoencapsulation. Nanomedicine. 2022 Feb 1;17 (5):325-47.
25. Alogna A, Lo Muzio FP, Catalucci D. Cardiovascular inhalation for targeted drug delivery in cardiac disease. Heart Failure Reviews. 2025 May 23:1-9.
26. .Niazi SK, Mariam Z. Computer-aided drug design and drug discovery: a prospective analysis. Pharmaceuticals. 2023 Dec 22;17 (1):22. .Kapetanovic I. Computer-aided drug discovery and development (CADDD): in silico-

chemico-biological approach. Chemico-biological interactions. 2008 Jan 30;171 (2):165-76.

27. Fox CS, Hall JL, Arnett DK, Ashley EA, Delles C, Engler MB, Freeman MW, Johnson JA, Lanfear DE, Liggett SB, Lusis AJ. Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association. Circulation. 2015 May 12;131 (19):1715-36.
28. Yang H, Li J, Song C, Li H, Luo Q, Chen M. Emerging Gene Therapy Based on Nanocarriers: A Promising Therapeutic Alternative for Cardiovascular Diseases and a Novel Strategy in Valvular Heart Disease. International Journal of Molecular Sciences. 2025 Feb 18;26 (4):1743.
29. Fox CS, Hall JL, Arnett DK, Ashley EA, Delles C, Engler MB, Freeman MW, Johnson JA, Lanfear DE, Liggett SB, Lusis AJ. Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association. Circulation. 2015 May 12;131 (19):1715-36.
30. De Araújo RS, da Silva-Junior EF, de Aquino TM, Scotti MT, Ishiki HM, Scotti L, Mendonça-Junior FJ. Computer-aided drug design applied to secondary metabolites as anticancer agents. Current Topics in Medicinal Chemistry. 2020 Jul 1;20 (19):1677-703.
31. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature reviews Drug discovery. 2010 Mar;9 (3):203-14.
32. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nature reviews immunology. 2006 Jul 1;6 (7):508-19.
33. Recinella L, Orlando G, Ferrante C, Chiavaroli A, Brunetti L, Leone S. Adipokines: new potential therapeutic target for obesity and metabolic, rheumatic, and cardiovascular diseases. Frontiers in physiology. 2020 Oct 30;11:578966.
34. Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nature reviews Drug discovery. 2004 Nov 1;3 (11):935-49.
35. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific reports. 2017 Mar 3;7 (1):42717.
36. Wang Y, Li Y, Chen J, Lai L. Modeling protein –ligand interactions for drug discovery in the era of deep learning. Chemical Society Reviews. 2025.
37. Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nature reviews Drug discovery. 2014 Sep;13 (9):655-72.
38. De Vivo M, Masetti M, Bottegoni G, Cavalli A. Role of molecular dynamics and related methods in drug discovery. Journal of medicinal chemistry. 2016 May 12;59 (9):4035-61.
39. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011 May 19;473 (7347):317-25.
40. Vosoughi P, Naghib SM, Mozafari MR. Stimuli-Responsive Nano/Biomaterials for Smart Drug Delivery in Cardiovascular Diseases: Promises, Challenges and Outlooks. Current Medicinal Chemistry. 2024 Nov 7.
41. Ali N, Hanif N, Khan HA, Waseem MA, Saeed A, Zakir S, Khan A, Aamir M, Ali A, Ali A, Saleem A. Deep learning and artificial intelligence for drug discovery, application, challenge, and future perspectives. Discover Applied Sciences. 2025 May 23;7 (6):533.
42. Merk D, Friedrich L, Grisoni F, Schneider G. De novo design of bioactive small molecules by artificial intelligence. Molecular informatics. 2018 Jan;37 (1-2):1700153.
43. Gómez-Bombarelli R, Wei JN, Duvenaud D, Hernández-Lobato JM, Sánchez-Lengeling B, Sheberla D, Aguilera-Iparraguirre J, Hirzel TD, Adams RP, Aspuru-Guzik A. Automatic chemical design using a data-driven continuous representation of molecules. ACS central science. 2018 Feb 28;4 (2):268-76.
44. Segler MH, Preuss M, Waller MP. Planning chemical syntheses with deep neural networks

and symbolic AI. Nature. 2018 Mar 29;555 (7698):604-10.

45. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A, Bridgland A. Highly accurate protein structure prediction with AlphaFold. nature. 2021 Aug 26;596 (7873):583-9.
46. Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, Donghia NM, MacNair CR, French S, Carfrae LA, Bloom-Ackermann Z, Tran VM. A deep learning approach to antibiotic discovery. Cell. 2020 Feb 20;180 (4):688-702.
47. Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy VA, Aladinskaya AV, Terentiev VA, Polykovskiy DA, Kuznetsov MD, Asadulaev A, Volkov Y. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nature biotechnology. 2019 Sep;37 (9):1038-40.
48. Lyu J, Wang S, Balius TE, Singh I, Levit A, Moroz YS, O'Meara MJ, Che T, Algaa E, Tolmachova K, Tolmachev AA. Ultra-large library docking for discovering new chemotypes. Nature. 2019 Feb 14;566 (7743):224-9.
49. Gorgulla C, Boeszoermenyi A, Wang ZF, Fischer PD, Coote PW, Padmanabha Das KM, Malets YS, Radchenko DS, Moroz YS, Scott DA, Fackeldey K. An open-source drug discovery platform enables ultra-large virtual screens. Nature. 2020 Apr 30;580 (7805):663-8.
50. Gentile F, Yaacoub JC, Gleave J, Fernandez M, Ton AT, Ban F, Stern A, Cherkasov A. Artificial intelligence–enabled virtual screening of ultra-large chemical libraries with deep docking. Nature Protocols. 2022 Mar;17 (3):672-97.
51. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, Li B, Madabhushi A, Shah P, Spitzer M, Zhao S. Applications of machine learning in drug discovery and development. Nature reviews Drug discovery. 2019 Jun;18 (6):463-77.
52. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug discovery today. 2019 Mar 1;24 (3):773-80.
53. Mak KK, Wong YH, Pichika MR. Artificial intelligence in drug discovery and development. Drug discovery and evaluation: safety and pharmacokinetic assays. 2024 Oct 22:1461-98.
54. Jiménez-Luna J, Grisoni F, Schneider G. Drug discovery with explainable artificial intelligence. Nature Machine Intelligence. 2020 Oct;2 (10):573-84.
55. Gorgulla C, Boeszoermenyi A, Wang ZF, Fischer PD, Coote PW, Padmanabha Das KM, Malets YS, Radchenko DS, Moroz YS, Scott DA, Fackeldey K. An open-source drug discovery platform enables ultra-large virtual screens. Nature. 2020 Apr 30;580 (7805):663-8.
56. Stein RM, Kang HJ, McCorvy JD, Glatfelter GC, Jones AJ, Che T, Slocum S, Huang XP, Savych O, Moroz YS, Stauch B. Virtual discovery of melatonin receptor ligands to modulate circadian rhythms. Nature. 2020 Mar 26;579 (7800):609-14.
57. Roggia M, Natale B, Amendola G, Di Maro S, Cosconati S. Streamlining large chemical library docking with artificial intelligence: the PyRMD2Dock approach. Journal of chemical information and modeling. 2023 Aug 8;64 (7):2143-9.

Cite: Sanika Sabale, Prasad Yadav, CADD in Cardiovascular Drug Discovery, Int. J. Med. Pharm. Sci., 2026, 2 (11), 89-106. https://doi.org/10.5281/zenodo.24414465